lenvima
LENVIMA® (lenvatinib) capsules, for oral use
Name | LENVIMA (lenvatinib) capsules |
Description | LENVIMA is a kinase inhibitor |
Indication |
Indicated for the treatment of:
|
Strengths |
4 mg and 10 mg Capsules Recommended dose:
In patients with severe renal or hepatic impairment, the dose is 14 mg once daily in DTC and 10 mg once daily in RCC. |
Regulatory Status |
EMA approved in June 2015; FDA approved in February 2015 Registered in Kuwait Under registration in GCC |
Business Partner | EISAI |